Brighter Pacific (00575.HK): Jiangsu Wanbang Pharmaceutical is currently advancing the new drug application for SenstendTM with the China National Medical Products Administration.

Wisdom Financial News App, Le Jingtai Pacific (00575.HK) announced that the company's strategic partner Jiangsu Wanbang Biochemical Pharmaceutical Group Co., Ltd. (Jiangsu Wanbang Medicine, a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.) is advancing the new drug application for SenstendTM with the National Medical Products Administration (NMPA) of China. Jiangsu Wanbang Medicine has received the first round of inquiries from the NMPA regarding the new drug application dossier and has promptly submitted a comprehensive response.